Efficacy and Safety of Perampanel as an Initial Monotherapy Therapy in Pediatric Focal Epilepsy
Objective:To investigate the efficacy and safety of perampanel(PER)as an initial monotherapy for focal epilepsy in children aged 4 to 12 years.Methods:We restrospectively analyzed the clinical data of pediatric patients with focal epilepsy who were treated at the neurology outpatient clinic of Quanzhou children's hospital between January to December 2022.All pediatric patients were treated with PER as initial monotherapy for at least 6 months.Treatment efficacy was evaluated by comparing seizure frequency before and after treatment,and statistical analysis categorized children into seizure-free and seizure-active,effective and ineffective groups based on seizure presence.Safety was evaluated by monitoring adverse events reported during the treatment period.Results:①A total of 42 pediatric patients with PER initial monotherapy for focal epilepsy met the inclusion criteria.②Significant differences were observed between the seizure-free and the group seizure-active,as well as between the treatment-effective and ineffective groups after 3 and 6 months of treatment(P<0.05).No significant differences were found in age,weight,duration of disease,number of seizures before treatment,and maintenance dose between the effective and ineffective groups at 6 months(P>0.05).However,a significant difference was noted in the number of seizures after treatment(P<0.05).③ A total of 6 adverse events were reported,including dizziness,irritability,and ataxia,all of which were mild and tolerable.Conclusion:Perampanel used as initial monotherapy for focal epilepsy in children,which demonstrates favorable efficacy and safety,making it a promising clinical option.
NETL
NSTL
万方数据
